The factors that regulate expression of genes in the 1C family of human cytosolic sulfotransferases (SULT1C) are not well understood. In a recent study evaluating the effects of a panel of transcription factor activators on SULT1C family member expression in LS180 human colorectal adenocarcinoma cells, we found that SULT1C2 expression was significantly increased by 1a,25-dihydroxyvitamin D 3 (VitD 3 ) treatment. The objective of our current study was to identify the mechanism responsible for VitD 3 -mediated activation of SULT1C2 transcription. VitD 3 treatment of LS180 cells activated transcription of a transfected luciferase reporter plasmid that contained ∼5 kilobase pairs (kbp) of the SULT1C2 gene, which included 402 nucleotides (nt) of the noncoding exon 1, all of intron 1, and 21 nt of exon 2. Although computational analysis of the VitD 3 -responsive region of the SULT1C2 gene identified a pregnane X receptor (PXR)-binding site within exon 1, the transfected 5 kbp SULT1C2 reporter was not activated by treatment with rifampicin, a prototypical PXR agonist. However, deletion or mutation of the predicted PXR-binding site abolished VitD 3 -mediated SULT1C2 transcriptional activation, identifying the site as a functional vitamin D response element (VDRE). We further demonstrated that vitamin D receptor (VDR) can interact directly with the SULT1C2 VDRE sequence using an enzyme-linked immunosorbent assay-based transcription factor binding assay. In conclusion, VitD 3 -inducible SULT1C2 transcription is mediated through a VDRE in exon 1. These results suggest a role for SULT1C2 in VitD 3 -regulated physiologic processes in human intestine.
Introduction
The cytosolic sulfotransferases (SULTs) are a family of conjugating enzymes that catalyze the biotransformation of a wide variety of exogenous and endogenous substrates. The human SULT1C subfamily consists of three members: SULT1C2, SULT1C3, and SULT1C4. The characterization of SULT1C substrate specificity, expression, and regulation is incomplete, but available evidence suggests that these enzymes might play metabolic roles during development (Runge-Morris and Kocarek, 2013) . Human SULT1C2 is expressed in multiple tissues, including fetal liver, stomach, and the vitamin D target tissues thyroid, intestine, and kidney (Runge-Morris and Kocarek, 2013). SULT1C2 does not metabolize prototypical SULT substrates but has been shown to sulfonate thyroid hormones and some phenols and to bioactivate the procarcinogen N-hydroxy-2-acetylaminofluorene (Sakakibara et al., 1998; Li et al., 2000; Allali-Hassani et al., 2007) .
We recently reported that treatment of LS180 human colorectal adenocarcinoma cells with several nuclear receptor activators, including 3-[3-[N-(2-chloro-3-trifluoromethylbenzyl)-(2,2-diphenylethyl)amino] propyloxy]phenylacetic acid (GW3965, liver X receptor agonist), 3-(2,6-dichlorophenyl)-4-(39-carboxy-2-chlorostilben-4-yl)oxymethyl-5-isopropylisoxazole (GW4064, farnesoid X receptor agonist), rifampicin (pregnane X receptor [PXR] agonist), or 1a,25-dihydroxyvitamin D 3 (VitD 3 , vitamin D receptor agonist), increased SULT1C2 expression (Rondini et al., 2014) . The VitD 3 -mediated induction was especially pronounced and occurred at the mRNA, protein, and promoter activation levels. It therefore seems likely that VitD 3 -mediated regulation of SULT1C2 could contribute to VitD 3 -regulated processes in intestine and possibly other VitD 3 target tissues, such as the kidney.
VitD 3 regulates gene transcription by activating the ligand-dependent nuclear receptor, vitamin D receptor (VDR), which binds as a heterodimer with retinoid X receptor (RXR) to vitamin D response elements (VDREs) in target genes (Haussler et al., 1997) . VDREs are classically direct repeats of AGGTCA separated by three nucleotides (i.e., DR3 motifs). We identified the cis-acting element responsible for VitD 3 -mediated regulation of SULT1C2 transcription.
Materials and Methods
Cell Culture. LS180 colorectal adenocarcinoma cells were obtained from the American Type Culture Collection (Manassas, VA) and were cultured as previously described elsewhere (Rondini et al., 2014) . Human embryonic kidney 293 (HEK293) cells used for protein expression were obtained from Dr. Ye-Shih Ho (Wayne State University, Detroit, MI) and were cultured in Dulbecco's modified Eagle medium supplemented with 100 U/ml penicillin, 100 mg/ml streptomycin, and 10% fetal bovine serum (all purchased from Life Technologies, Grand Island, NY). Cells were maintained under a humidified atmosphere of 95% air, 5% CO 2 at 37°C.
Preparation of Firefly Luciferase Reporter Plasmids. Preparation of the SULT1C2 (24998:21)-firefly luciferase (Luc) reporter plasmid has been described previously elsewhere where it was referred to as SULT1C2#2 (Rondini et al., 2014 Transient Transfection Analysis. Approximately 200,000 LS180 cells were seeded into the wells of 12-well plates. Seventy-two hours later, the cultures were transfected with 1.6 mg of a SULT1C2-Luc reporter plasmid and 1 ng of the Renilla luciferase expression plasmid, pRL-CMV (Promega), as previously described elsewhere (Rondini et al., 2014) . After 18 hours, the transfection medium was replaced, and the cells were treated with 0.1% ethanol (SigmaAldrich, St. Louis, MO) or 0.1 mM VitD 3 (Sigma-Aldrich) for 48 hours. The cells were harvested for measurement of firefly and Renilla luciferase activities using the Dual Luciferase Assay (Promega) and a GloMax Luminometer (Promega).
VDR•VDRE In Vitro Binding Assay. A VDR expression plasmid was prepared by amplifying the VDR coding sequence (RefSeq NM_000376.2), using LS180 cDNA as template, Herculase II Fusion DNA Polymerase (Agilent Technologies), and the primers listed in Supplemental Table 1 . The amplified fragment was digested with HindIII and XhoI and ligated into the pcDNA3.1 expression plasmid (Life Technologies). Approximately 1,000,000 HEK293 cells were seeded into 100-mm plates. On reaching 70%-80% confluency, the cells were transfected with 60 ml Lipofectamine 2000 (Life Technologies), 1.5 mg of VDR-pcDNA3.1, and 1.5 mg RXRa-pSG5 (provided by Dr. Steven Kliewer, University of Texas Southwestern, Dallas, TX). Forty-eight hours later, nuclear proteins were extracted using the NucBuster Protein Extraction kit (Novagen; EMD Millipore, Billerica, MA), and protein concentrations were quantified using the bicinchoninic acid protein assay (Thermo Fisher Scientific, Rockford, IL).
The Universal EZ-TFA Chemiluminescent Transcription Factor Assay (EMD Millipore) was performed according to the manufacturer's protocol. Briefly, 0.75 mg of HEK293 nuclear extract containing VDR and RXRa, 2 pmol biotinylated capture probe containing the VDRE consensus sequence from the rat osteocalcin gene (also known as bone g-carboxyglutamate, official symbol Bglap; Markose et al., 1990; Demay et al., 1992) , and transcription factor assay buffer were added to the wells of a streptavidin-coated microplate.
Competition for binding of VDR to the capture probe was assessed by adding one of the following unlabeled double-stranded oligonucleotides to the binding reaction: 1) consensus VDRE, 2) mutated consensus VDRE (Gutierrez et al., 2004) , 3) SULT1C2 VDRE, or 4) mutated SULT1C2 VDRE. The competitors were added at 1.5-to 50-fold molar excess of the biotinylated capture probe. Background binding was determined by assessing VDR binding to a biotinylated mutated consensus VDRE probe. Capture probe, competitor probe, and negative control probe sequences are listed in Supplemental Table 1 . Capture probe-bound VDR was detected using the primary antibody VDR (D-6) X (sc-13133X; Santa Cruz Biotechnology, CA) diluted 1:5000, followed by horseradish peroxidaseconjugated secondary antibody (1:500 dilution). Chemiluminescence was measured using kit reagents and a GloMax Luminometer. Data are expressed relative to VDR•RXR binding to the consensus VDRE capture probe in the absence of a competitor.
Statistical Analysis. Transfection and transcription factor binding assay data were analyzed using one-way analysis of variance followed by the NewmanKeuls or Dunnett's multiple comparison test. P , 0.05 was considered statistically significant. Binding curves with 95% confidence intervals were generated using the sigmoidal dose-response algorithm of Prism 6 for Windows (GraphPad Software, La Jolla, CA).
Results and Discussion
We previously reported that VitD 3 treatment of LS180 cells increased activity from a transfected reporter plasmid containing ;5 kilobase pairs (kbp) of the SULT1C2 gene (24998:21 relative to the translation start site in exon 2, shown schematically in Fig. 1) (Rondini et al., 2014) . Recently, in a genomewide chromatin immunoprecipitation sequencing analysis of VitD 3 -treated LS180 cells, Meyer et al. (2012) detected a VDR•RXR binding peak at nucleotides (nt) 108,288,453 to 108,289,105 of chromosome 2 (Gene Expression Omnibus GSE31939; RefSeq NC_000002.12), with the peak center located within the SULT1C2 noncoding exon 1. This information suggested that a VDRE site is located near the 59-end of our SULT1C2 (24998:21) fragment.
We therefore deleted 171 nt from the 59-end of SULT1C2 (24998:21), creating the SULT1C2 (24827:21)-Luc reporter. Figure 2 shows that this deletion abolished VitD 3 -mediated SULT1C2 activation, confirming the presence of a VitD 3 -responsive site in this region.
MatInspector software was used to identify putative transcription factor-binding sites within the deleted 171 nt sequence. Instead of detecting a prototypical VDR•RXR DR3 motif in exon 1, a motif identified as a putative PXR•RXR binding site was detected at nt 24887 to 24863 (predicted PXR response element; Fig. 1 ). However, we previously had reported that treatment of LS180 cells with the prototypical PXR agonist rifampicin did not increase expression from the SULT1C2 (24998:21)-Luc reporter (Rondini et al., 2014) , suggesting that the computationally-predicted sequence is not a functional PXR response element but rather potentially a VDRE site. Mutation of the core sequence of the predicted PXR-binding site (from GGT to AAC) within the SULT1C2 (24998:21)-Luc plasmid caused a 94% reduction in VitD 3 -mediated SULT1C2 reporter activation compared with the wildtype construct (Fig. 3) , further supporting the conclusion that this site is a functional VDRE.
An enzyme-linked immunosorbent assay-based transcription factor-binding assay was used to determine whether VDR•RXR can bind directly to the VDRE site in exon 1 of the human SULT1C2 gene. The capture probe containing the VDRE consensus sequence from the rat osteocalcin gene promoter was incubated with unlabeled competitor probes added in 50-fold molar excess and nuclear protein extract from HEK293 cells expressing VDR and RXRa. The SULT1C2 VDRE competitor significantly inhibited VDR•RXR binding to the capture probe by 74%, which was similar to the inhibition (79%) that was observed when consensus VDRE competitor was added (Fig. 4) . Mutated consensus and SULT1C2 VDRE competitors did not significantly inhibit binding to the capture probe (25% and 31% inhibition, respectively). Incubation with increasing amounts (1.5-to 50-fold molar excess) of SULT1C2 VDRE competitor inhibited VDR•RXR binding to the capture probe with an IC 50 that was comparable to that of the consensus VDRE competitor (Fig. 4, inset) .
VDR and PXR are both members of the NR1I nuclear receptor group and therefore have high sequence similarity (Kliewer et al., 1998) . Additionally, they have been shown to recognize similar ligands and regulate similar target genes. For example, VDR and PXR are both activated by the secondary bile acid lithocholic acid (Staudinger et al., 2001; Makishima et al., 2002) , and both receptors regulate expression of CYP3A4 (Bertilsson et al., 1998; SchmiedlinRen et al., 2001; Thummel et al., 2001 ). In the case of CYP3A4, PXR and VDR activate transcription through the same cis-acting elements, a proximal everted repeat with six intervening nucleotides motif and a distal DR3 motif (Goodwin et al., 1999; Thummel et al., 2001; Thompson et al., 2002) . By comparison, although both PXR and VDR activate SULT1C2 expression in LS180 cells (Rondini et al., 2014) , in this case the two receptors do not appear to use the same response element. VitD 3 treatment activates SULT1C2 transcription through the element at nt 24887 to 24863, but rifampicin treatment did not increase transcription from the (24998:21) reporter construct containing that element (Rondini et al., 2014) . Therefore, VDR/PXR regulation of CYP3A4 differs somewhat from SULT1C2 regulation by these two receptors. Presumably the restriction by the SULT1C2 motif to VDR is physiologically important for ensuring appropriate SULT1C2 expression in response to hormonal versus xenobiotic signals. Further research is needed to determine the role that this mode of regulation plays in intestinal physiology. An enzyme-linked immunosorbent assay-based in vitro transcription factor-binding assay was performed as described in Materials and Methods. Binding reactions contained nuclear protein extract and a biotinylated consensus or mutated VDRE capture probe, alone or in the presence of a 50-fold molar excess of either wild-type (WT) or mutated (Mut) consensus VDRE or WT or Mut SULT1C2 VDRE competitor probe. Each bar represents the mean 6 S.E.M. binding of VDR•RXR to a VDRE capture probe relative to the binding to the consensus VDRE capture probe that was detected in the absence of competitor (n = 4, derived from the means of four independent binding experiments, each performed with duplicate wells). ***Significantly different from consensus VDRE capture probe in absence of competitor, P , 0.001. Inset: Binding affinity was assessed by adding different amounts (1.5-to 50-fold molar excess) of competitor probes to the consensus VDRE capture probe and nuclear protein extract. IC 50 values with 95% confidence intervals (CI) are shown. Each data point is the mean from two independent experiments, each performed in duplicate wells.
